News & Press: Latest News

MDMA Statement on Committee Passage of the “Local Coverage Determination Clarification Act”

Wednesday, September 5, 2018  
Share |

MDMA  Statement on Committee Passage of the “Local Coverage Determination Clarification Act of 2017”

 

Washington, D.C. – Mark  Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA), issued the following statement today regarding passage in the House Ways and Means Committee of H.R. 3635, the “Local Coverage Determination Clarification Act of 2017:”

“Medical technology innovators continue to work tirelessly as they develop the cures and therapies of tomorrow, and it is critical that patients and providers have access to them.  The ‘Local Coverage Determination Clarification Act of 2017’ builds upon past efforts to establish a more reasonable and transparent environment for making coverage decisions within Medicare, including the establishment of a formal  CMS  appeals process for a local coverage denial.

“MDMA remains committed to working with Congress to help improve the reimbursement landscape so that patients throughout the United States get timely access to medical technology innovation.”

###